vVARDIS Holding AG announced a strategic minority investment from funds managed by Apollo Global Management, supporting the company’s global expansion and establishing it as a billion-dollar-plus healthcare company.
The investment will accelerate the commercial rollout of vVARDIS’ Curodont platform, a non-invasive treatment designed to address tooth decay without drilling. The company’s peptide-based formulations enable enamel repair by promoting the formation of crystalline structures within lesions, offering an alternative to traditional restorative procedures.
Curodont has gained traction in the United States since its launch, with approximately 3 million teeth treated and adoption across nearly 20 percent of general dental practices. The technology is positioned as a solution for early-stage cavities, addressing a significant unmet need in dentistry where treatment options have historically relied on invasive methods.
vVARDIS plans to use the funding to expand its presence in key markets across the United States and Europe, scaling commercialization efforts and increasing adoption among dental professionals. The company’s founders and co-CEOs, Drs. Haley and Goly Abivardi will retain a majority ownership stake following the transaction.
The investment underscores growing demand for non-invasive, science-driven approaches to dental care, particularly as oral health continues to be linked to broader health outcomes. Tooth decay remains one of the most prevalent non-communicable diseases globally, affecting a majority of adults and contributing to long-term health risks if left untreated.
vVARDIS is positioning its technology within a broader shift toward preventive and minimally invasive treatments, supported by clinical research and increasing adoption across dental practices. The company is targeting a large addressable market in the United States, with opportunities to redefine treatment standards in oral health.
KEY QUOTES:
“vVARDIS has built a differentiated business, with Drs. Haley and Goly Abivardi pioneering a new category in dental care backed by peer-reviewed clinical studies. Apollo Funds’ investment supports the company’s continued expansion in key markets across the U.S. and Europe, bringing this restorative therapy to more practices and patients worldwide.”
Jeremy Honeth, Partner, Apollo And Andrea Vanni, Managing Director, Apollo
“Curodont fills a longstanding gap in dentistry: when prevention fails, dentists now have a quick, easy-to-use non-invasive treatment free of drilling and needles. The rapid adoption of Curodont reflects the urgency of that unmet need. Apollo Funds’ investment strengthens our commercial foundation in the U.S. and Europe and enables us to scale this environmentally sustainable technology across markets.”
Haley Abivardi, Co-CEO And Co-Founder, vVARDIS
“Our mission is to bring a medical, science driven approach to dentistry. Using peptide-containing formulations, our non-invasive technology is an innovative treatment designed to treat tooth decay without drilling and without polymer materials. Apollo Funds’ investment reinforces our leadership in generative dentistry and advances the future of oral science.”
Goly Abivardi, Co-CEO And Co-Founder, vVARDIS
